Tenofovir disoproxil for the treatment of chronic hepatitis B

Hepatitis B - tenofovir disoproxil fumarate: review decision - October 2011  information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

Hepatitis B - tenofovir disoproxil fumarate: review proposal - July 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 74 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)

Hepatitis B - tenofovir disoproxil fumarate: final appraisal determination information

Hepatitis B - tenofovir disoproxil fumarate: final appraisal determination

Hepatitis B - tenofovir disoproxil fumarate: final appraisal determination (PDF 78 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 92 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation from Evidence Review Group (Southampton Health Technology Assessment Centre)

Response to consultee, commentator and public comments on the ACD and comments from website consultation from Evidence Review Group (Southampton Health Technology Assessment Centre) (PDF 94 KB)

Consultee and commentator comments on the ACD

Bristol Myers Squibb

Bristol Myers Squibb (PDF 61 KB)

Department of Health

Department of Health (PDF 19 KB)

Gilead

Gilead (PDF 32 KB)

Gilead - comparisons

Gilead - comparisons (PDF 54 KB)

Hepatitis B Foundation UK

Hepatitis B Foundation UK (PDF 20 KB)

Roche

Roche (PDF 23 KB)

Royal College of Nursing

Royal College of Nursing (PDF 18 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 31 KB)

South Asian Health Foundation

South Asian Health Foundation (PDF 19 KB)

Welsh Assembly Government

Welsh Assembly Government (PDF 11 KB)

Dr Mark Nelson

Hepatitis B - tenofovir disoproxil fumarate: appraisal consultation

Hepatitis B - tenofovir disoproxil fumarate (appraisal consultation document) information

Evidence considered

Pre-meeting briefing

Pre-meeting briefing (PDF 135 KB)

EMEA Assessment Report

EMEA Assessment Report (PDF 307 KB)

Hepatitis B - tenofovir disoproxil fumarate: evidence review group report

Hepatitis B - tenofovir disoproxil fumarate: evidence review group report (PDF 1.21 MB)

Clarification letter

Clarification letter

Clarification letter (PDF 110 KB)

Manufacturer clarification response

Manufacturer clarification response (PDF 517 KB)

Non-manufacturer submissions

Association of Clinical Microbiologists

Association of Clinical Microbiologists (PDF 37 KB)

Hepatitis B Foundation UK

Hepatitis B Foundation UK (PDF 33 KB)

Royal College of Physicians

Royal College of Physicians (PDF 53 KB)

Manufacturer submission

Manufacturer submission (PDF 1.65 MB)

Patel

Hepatitis B - tenofovir disoproxil fumarate: final scope

Hepatitis B - tenofovir disoproxil fumarate: response to consultee and commentator comments on the draft scope

Hepatitis B - tenofovir disoproxil fumarate: response to consultee and commentator comments on the provisional matrix